Pancreatic Cancer Research

ResearcherUnited States Department of Veterans AffairsNo recent work listed

Sripathi M. Sureban

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5476-9593; OpenAlex author ID A5036779154. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper

Papers 3

  1. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. Co-author DOI 10.1371/journal.pone.0118933↗
  2. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase… Co-author DOI 10.1186/1476-4598-13-103↗
  3. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0073940↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nathaniel Weygant · 3 shared papers, 2013–2015 · strength 0.11
  2. Courtney W. Houchen · 3 shared papers, 2013–2015 · strength 0.11
  3. Dongfeng Qu · 3 shared papers, 2013–2015 · strength 0.11
  4. Ralf Janknecht · 1 shared paper, 2014 · strength 0.04
  5. James Randolph Sanders Hocker · 1 shared paper, 2015 · strength 0.04
  6. Guangyu An · 1 shared paper, 2015 · strength 0.04
  7. Nicole M. Aiello · 1 shared paper, 2015 · strength 0.04
  8. Ben Z. Stanger · 1 shared paper, 2015 · strength 0.04
  9. Jay S. Hanas · 1 shared paper, 2015 · strength 0.04
  10. Andrew D. Rhim · 1 shared paper, 2015 · strength 0.04
  11. Shubham Pant · 1 shared paper, 2015 · strength 0.04
  12. Chinthalapally V. Rao · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.